Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TXNRD1 | Q16881 | 5/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7535509 | 0.90 | VCAM1 (0.47) | VCAM1MEN1KMT2ARAB9ATXNRD1 | |
| SCHEMBL7540192 | 0.85 | TXNRD1 (0.55) | VCAM1MEN1KMT2ARAB9ATXNRD1 | |
| SCHEMBL7540492 | 0.82 | VCAM1 (0.71) | VCAM1KMT2ANPSR1MAPTALDH1A1 | |
| SCHEMBL7537002 | 0.78 | SLC22A12 (0.43) | TAS2R14 | |
| SCHEMBL6343160 | 0.76 | TUBB4A (0.56) | MEN1KMT2ANPSR1ALDH1A1GAA | |
| SCHEMBL6680388 | 0.76 | ALDH1A1 (0.61) | VCAM1MEN1KMT2ANPSR1MAPT | |
| SCHEMBL2313760 | 0.75 | VCAM1 (0.69) | VCAM1MEN1KMT2ARAB9ATXNRD1 | |
| SCHEMBL6339080 | 0.75 | TUBB4A (0.55) | ALDH1A1GAALMNAHTTPKM | |
| SCHEMBL7534384 | 0.74 | VCAM1 (0.58) | VCAM1MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL7540386 | 0.73 | VCAM1 (0.66) | VCAM1MEN1KMT2ANPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | AMGEN INC. | 2002-01-31 | — | — | US | claimed |
| EP-1005453-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK, INC. (US) | 2000-06-07 | — | — | EP | claimed |
| WO-1999010320-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK INC. (US) | 1999-03-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | CYP46A1, TGFB1, NR1H2 | VCAM1 51/4885MEN1 2231/4885KMT2A 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.